Actinium Pharmaceuticals (ATNM)

• Market cap: $34.8M
• 1 day: -5.13%
• 5 days: -15.27%
• 1 month: 12.12%
• 3 months: -4.31%
• 6 months: -21.83%
• Year to date: -18.98%
• 1 year: -26.97%
• 5 years: -85.51%
• 10 years: -98.03%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.

Employees: 25